Discovery of new small molecules inhibitors for EphB4 receptor tyrosine kinase with a fragment-based drug design approach

Year 2025, , 75 - 89, 05.01.2025

Amine Ballari , Rachid Haloui , Ossama Daouı , Khaoula Mkhayar , Khadija Khaddam Allah Samir Chtita , Abdelmoula El Abbouchi , Souad Elkhattabi

https://doi.org/10.33435/tcandtc.1430900

Abstract

Erythropoietin-producing hepatocellular carcinoma B4 (EphB4) belongs to the Eph family of receptor tyrosine kinases (RTKs) and plays a significant role in the amplification of many kinds of cancers such as lung cancer, head and neck cancer, and mesothelioma. In this work, we applied a fragment-based drug design strategy to find novel Ephb4 receptor inhibitors as potential therapeutic candidates. A screening of over 269,000 fragments from various libraries has been conducted to determine their affinity for binding EphB4. Using Schrödinger software, 1,000 fragments with the highest docking scores underwent fragment linking to generate 100 new molecules. The EphB4 binding affinity and ADMET characteristics of the top 20 docking score molecules were then examined in more detail. After the best compounds were selected, a molecular dynamics study was conducted to determine the stability of the ligand-receptor complex in the top three molecules. The resultant compound may be investigated further in the context of tyrosine kinase inhibitor drug development.

Keywords

Tyrosine kinase inhibitors, EphB4, Fragment-based drug design, Molecular docking, Molecular dynamics

References

• [1] L. R. de Souza Neto, J. T. Moreira-Filho, B. J. Neves, R. L. B. R. Maidana, A. C. R. Guimarães, N. Furnham, C. H. Andrade, F. P. Silva, In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery. Frontiers in chemistry 8 (2020) 93.
• [2] M. K. Paul, A. K. Mukhopadhyay, Tyrosine kinase-Role and significance in Cancer, International journal of medical sciences 1 (2004) 101–115.
• [3] C. C. Ayala-Aguilera, T. Valero, Á. Lorente-Macías, D. J. Baillache, S. Croke, A. Unciti-Broceta, Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis, Journal of medicinal chemistry 65 (2022), 1047–1131.
• [4] J. Rudolph, J. J. Crawford, K. P. Hoeflich, J. Chernoff, p21-activated kinase inhibitors, The Enzymes 34 (2013) 157–180.
• [5] K. Kullander, R. Klein, Mechanisms and functions of Eph and ephrin signalling, Nature reviews. Molecular cell biology 3 (2002) 475–486.
• [6] R. Salgia, P. Kulkarni, P. S. Gill, EphB4: A promising target for upper aerodigestive malignancies, Biochimica et biophysica acta. Reviews on cancer 1869 (2018), 128–137.
• [7] Q. Li, Application of Fragment-Based Drug Discovery to Versatile Targets, Frontiers in molecular biosciences 7 (2020), 180.
• [8] J. Mortier, C. Rakers, R. Frederick, G. Wolber, Computational Tools for In Silico Fragment-Based Drug Design, Current topics in medicinal chemistry 12 (2012), 1935–1943.
• [9] Schrödinger Release 2024-3: Maestro, Schrödinger, LLC, New York, NY, 2024.
• [10] https://www.rcsb.org/structure/3ZEW December 2013, Accessed: 10.12.2023.
• [11] Schrödinger Release 2024-3: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2024; Impact, Schrödinger, LLC, New York, NY; Prime, Schrödinger, LLC, New York, NY, 2024.
• [12] Schrödinger Release 2020-3: LigPrep, Schrödinger, LLC, New York, NY, 2020.
• [13] Schrödinger Release 2020-3: Glide, Schrödinger, LLC, New York, NY, (2020).
• [14] C. Choudhury, Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease, Journal of biomolecular structure & dynamics 39 (2021) 3733–3746.
• [15] Schrödinger Release 2024-3: QikProp, Schrödinger, LLC, New York, NY, 2024.
• [16] T. Darden, D. York, L. Pedersen, Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems, Journal of Chemical Physics 98 (1993) 10089–10092.
• [17] H. Jhoti, G. Williams, D. C. Rees, C. W. Murray, The “rule of three” for fragment-based drug discovery: where are we now?, Nature Reviews Drug Discovery 12 (2013), 644.
• [18] S. Genheden, U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert opinion on drug discovery, 10 (2015) 449–461.
• [19] C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced drug delivery reviews 46 (2001) 3–26.
• [20] D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, Journal of medicinal chemistry 45 (2002) 2615–2623.